ABSTRACT Discovered 20 years ago, fibroblast growth factor (FGF)19, and its mouse ortholog FGF15, were the first members of a new subfamily of FGFs able to act as hormones. During fetal life, FGF15/19 is involved in organogenesis, affecting the development of the ear, eye, heart, and brain. At adulthood, FGF15/19 is mainly produced by the ileum, acting on the liver to repress hepatic bile acid synthesis and promote postprandial nutrient partitioning. In rodents, pharmacologic doses of FGF19 induce the same antiobesity and antidiabetic actions as FGF21, with these metabolic effects being partly mediated by the brain. However, activation of hepatocyte proliferation by FGF19 has long been a challenge to its therapeutic use. Recently, genetic reengineering of the molecule has resolved this issue. Despite a global overlap in expression pattern and function, murine FGF15 and human FGF19 exhibit several differences in terms of regulation, molecular structure, signaling, and biological properties. As most of the knowledge originates from the use of FGF19 in murine models, differences between mice and humans in the biology of FGF15/19 have to be considered for a successful translation from bench to bedside. This review summarizes the basic knowledge concerning FGF15/19 in mice and humans, with a special focus on regulation of production, morphogenic properties, hepatocyte growth, bile acid homeostasis, as well as actions on glucose, lipid, and energy homeostasis. Moreover, implications and therapeutic perspectives concerning FGF19 in human diseases (including obesity, type 2 diabetes, hepatic steatosis, biliary disorders, and cancer) are also discussed. (Endocrine Reviews 39: 960 -989, 2018) 
O verweight and obesity, caused by unhealthy eating and reduced physical activity, are rapidly rising worldwide with the consequence of increasing the prevalence of type  diabetes (TD) (, ). Obesity, TD, and related insulin resistance are associated with complications involving angiopathies and nerve damages, but also liver-related diseases (). Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disorder related to obesity and TD (, ). A subset of NAFLD patients develop a state of hepatic inflammation [nonalcoholic steatohepatitis (NASH)], which can progress to fibrosis, cirrhosis, and ultimately result in hepatocellular carcinoma (HCC) (). Apart from lifestyle changes, including weight loss and physical activity, there is currently no efficient long-term drug to improve and/or avoid development and progression of obesity, TD, and NAFLD.
Fibroblast growth factors (FGFs) form a large family of . signaling molecules with pleiotropic functions in different areas of biology (). FGFs bind and signal through four membrane tyrosine kinase receptors [FGF receptors (FGFRs  to )] (-). The FGFRs present the same overall structure, with an extracellular ligand-binding domain (composed of three immunoglobulin-like domains), a transmembrane domain, and an intracellular tyrosine kinase domain (-). Splice variants for FGFR, FGFR, and FGFR exhibit differential binding selectivity for FGFs whereas no splice variants are known for FGFR (). FGFs also bind components of the extracellular matrix such as heparan sulfate and heparan sulfate proteoglycan (, ). This interaction increases the stability and affinity of FGFs for FGFRs and limits their diffusion within the local environment (, ). In fact, FGFs classically signal through a paracrine manner, especially between epithelium and mesenchyme (). FGFs and FGFRs present highly specific expression patterns, determining selectivity of their sites of action (). Moreover, the expression of FGFs and FGFRs is temporally regulated. Some FGFs are mainly expressed during development whereas others are more involved in adult tissues homeostasis ().
For many years, investigations concerning FGFs mainly focused on proliferation, migration, and differentiation processes, in particular in the field of developmental biology (). The recent discovery of a new subgroup of FGFs, namely endocrine FGFs, has stimulated medical research in the field. Although FGF/, FGF, and FGF, the three endocrine FGFs, present different structures and functions, they all bind poorly to heparin and derivatives (). This allows these FGFs to diffuse beyond the interstitial space to reach the bloodstream and act far from their tissue of origin, as classical endocrine hormones (). In this way, FGF derived from bone acts on the kidney to regulate phosphate reabsorption and vitamin D production, representing an important endocrine loop in the control of mineral homeostasis ().
FGF, mainly produced by the liver during metabolic stress, regulates numerous metabolic processes, including glucose and lipid homeostasis. Thus, it represents an interesting candidate for treatment of obesity and TD ().
The present review will deal with FGF and its mouse ortholog FGF, with particular focus on the regulation of its production, its physiological and pharmacological actions, as well as its involvement in human diseases and potential use in the treatment of metabolic and gastrointestinal diseases. As much of the basic knowledge in the field of FGF/ biology comes from murine studies, species differences in the functions of FGF/ between rodents and humans will also be highlighted in a translational perspective.
Molecular Biology of FGF15/19
FGF15/19 gene and protein Murine FGF was initially identified as a downstream target of the chimeric oncoprotein EA-Pbx in the NIHT cell line (). The FGF gene is located on chromosome  and consists of  exons. The FGF protein, composed of  amino acids, is the most divergent among the known FGF family members (). Subsequent screening of expressed sequence tags led to the discovery of FGF cDNA from human neuroepithelial cells showing sequence homology with the corresponding region of mouse FGF (). The chromosomal location of FGF was found to be chromosome q., a genetic region associated with an osteoporosis-pseudoglioma syndrome (). The whole FGF coding region revealed a complete protein sequence of  amino acids sharing % similarity with mouse FGF (). The homology between the human FGF and mouse FGF was significantly less than that observed between most human and mouse FGF orthologs (), explaining their divergent names. However, based on the evolutionary conservation of the CCND-ORAOV-FGF-FGF locus from zebrafish to humans, it was concluded that the human FGF gene was the ortholog of the murine FGF gene ().
FGF15/19 structure and affinity for receptors/coreceptors
Compared with other FGFs, the key heparin-binding sites of FGF have radically different conformations and charge patterns (, ). In particular, the conformation of the heparin-binding region between b-strands  and  in FGF diverges completely from the analog region of paracrine-acting FGFs (). A cleft between this region and the b-b loop (the other heparin-binding region) precludes direct interaction between FGF and heparin/heparan sulfate (), reducing the heparin-binding affinity and facilitating the endocrine function (). These conformational predictions are confirmed by in vitro The coreceptor b-Klotho (KLB) has emerged as a compensatory mechanism for the poor ability of heparin/heparan sulfate to promote binding of FGF to cognate receptors (). KLB is a single-pass membrane protein consisting of two internal repeats with homology to family  glycosidases (). Crystal structures of KLB extracellular regions reveal that its glycosidase substrate-binding domain has evolved to recognize a sugar-mimicking Ser-Pro-Ser motif present in FGF (). Use of chimeric proteins developed from members of the endocrine FGF subfamily and Klotho family identified the C-terminal tail of FGF as being required for KLB recognition and signaling (). Interestingly, FGF possesses a unique unpaired cysteine (Cys  ) that permits dimerization of monomers and is absent in FGF and all other endocrine FGFs (). This structural feature can explain functional divergence from the human FGF.
FGF exhibits a high specificity for FGFR binding (). Unique sequences in both FGF and FGFR are key to the formation of the complex, offering a conformational explanation for this unusual selective affinity (). Different amino acids at both the N and C termini of FGF contribute to full FGFR activation (). Nevertheless, amino acid residues  to  of FGF are sufficient to confer FGFR activation to other endocrine FGFs ().
Whether FGF/ can directly interact with FGFR in the absence of KLB remains controversial and possibly concentration-dependent (-). Whereas FGFR is only activated by FGF among endocrine FGFs, FGF can also bind and signal through other FGFRs. In fact, FGF binds FGFR with comparable affinity to FGFR in the presence of KLB (). Furthermore, FGF can signal through FGFR- bound by KLB (-), especially at a supraphysiological concentration (). Additionally, each FGFR isoform (originating from splice variants) has a different affinity for KLB. FGFRc and FGFR bind KLB more potently than FGFRc or FGFRc whereas type b isoforms of FGFRs fail to interact with KLB (). As a consequence, FGFR isoform composition also impacts FGF/ binding to KLB-FGFR complexes.
In contrast to the wide distribution of FGFRs in the body, the pattern of Klotho protein expression is more limited () and defines the main tissue targets of endocrine FGFs. In mice, the FGFR gene is highly expressed in kidney, liver, lung, and adrenal, whereas KLB expression is high in enterohepatic tissues (liver, gallbladder, colon, and pancreas) and white adipose tissue/brown adipose tissue (BAT) (). The liver is the only organ in which FGFR and KLB are abundantly coexpressed (, , ) and is in consequence the main target tissue of FGF/. In line with this concept, early response genes are only induced in the liver of FGF-injected mice (). FGF can also signal through FGFRs associated with lactase-like Klotho (). However, the biological relevance of this signaling complex remains unknown.
FGF15/19 intracellular signaling pathways
FGFs mediate their cellular responses by the binding and activation of FGFR- (, ). FGF/FGFR interaction induces receptor dimerization, activation, and autophosphorylation of multiple tyrosine residues in the cytoplasmic domain (, , ).
Most of the knowledge concerning intracellular events mediating FGF/ actions comes from in vitro work involving various cell lines. In transfected HEK, L, T-L, and Caco- cell lines, FGF induces phosphorylation of FGFR substrate a (FRSa) and ERK/ (, , , ). FGF also activates the mammalian target of rapamycin complex -pSK and ERK-pRSK pathways independently to regulate S in an additive manner in hepatoma cells and in T-L adipocytes (). FGF signals to mammalian target of rapamycin complex  through Ras-like protein to regulate gene expression in HepG cells (). FGF signaling through FGFR phosphorylates the inhibitor of nuclear factor kB kinase subunit b in HEK and DU cell lines, inhibiting inflammation through the downregulation of nuclear factor kB (). Beyond phosphorylation cascades, FGF stimulates the transcription of early response genes (c-Fos, JunB, and c-Jun) in HepG and HepB cell lines (). FGF also increases small heterodimer partner (SHP) protein stability by inhibiting its ubiquitination and proteasomal degradation (). Finally, in primary cultures, FGF activates the c-Jun N-terminal kinase pathway in human hepatocytes (), induces phosphorylation of forkhead box O (FoxO) in mouse hepatocytes (), and increases the phosphorylation of signal transducer and activator of transcription  (STAT) in rat hepatocytes ().
Intracellular signaling downstream of FGF/ has also been investigated in vivo. Acute FGF administration induces phosphorylation of ERK/ (, ) and c-Fos expression () in mouse liver. The phosphorylation of ERK/, as well as several other signaling events triggered by FGF/, such as the activation of ribosomal S kinase (pRSK), SHP upregulation, and protein kinase C phosphorylation, appears dependent on the presence of the nonreceptor tyrosine phosphatase with two Src homology  domains in mouse liver (). Src homology  forms a complex with FRSa and Gab upon FGF stimulation (). Chronic FGF overexpression increases the hepatic phosphorylation of both FoxO and protein kinase B (also known as Akt) (). FGF also increases the phosphorylation of eukaryotic translation initiation factor B, eukaryotic translation initiation factor E, ribosomal protein S, FRSa, ERK, pRSK, glycogen synthase kinase (GSK)a, and GSKb in mouse liver (). Importantly, FGF equally induces hepatic STAT phosphorylation (-). Administration of FGF to mice also activates the phosphorylation of the ERK/ signaling pathway in extrahepatic tissues, including adipose tissue (), the hypothalamus (), and the ileum ().
Note that concentrations of FGF/ used in these in vitro and in vivo studies can be several orders of magnitude higher than the maximal circulating values observed in animals or humans, even postprandially or following pharmacologic/nutritional stimulation. Although higher levels of FGF/ can be present in the portal circulation compared with the systemic blood circulation, one should be cautious concerning direct translation of the basic signaling studies to human physiology. The main intracellular signaling pathways mediating FGF/ actions in hepatocytes are illustrated in Fig.  .
Production of FGF15/19
Tissue specificity of FGF15/19 expression During murine development, the FGF gene is predominantly expressed in the nervous system, the pharyngeal pouches, and the tail bud (). FGF expression first appears at embryonic day (E). in the mouse neuroectoderm before exhibiting a highly dynamic expression pattern during brain development (). In the diencephalon, strong FGF expression is initially seen in the dorsal thalamus before the extension to the ventral thalamus (). In the mesencephalon, FGF is first expressed caudally before being predominantly observed rostrally at later developmental stages (). In the telencephalon, FGF is detected in the olfactory bulb region (). FGF expression is also detected in the inner cell layer of the optic cup, in the rostral hindbrain regions (rhombomeres  and ), in the caudal hindbrain, in the cervical spinal cord, and in the terminal rostral hypothalamus (, ). In contrast, during adulthood, FGF globally disappears from the central nervous system (), although recent work found FGF expression in specific neurons of the dorsomedial hypothalamus and the perifornical area (). Instead, the FGF gene is highly expressed in the ileum (distal part of the intestine) and also detected in the jejunum and duodenum (more proximal intestine segment) of adult mice (, ). At the cellular level, FGF expression is detected in the enterocytes of the villus epithelium associated to the coreceptor KLB. After recruitment of docking and adapter proteins, FGFR4 activation regulates the activity of several protein kinases and transcription factors involved in different biological processes. Green arrows represent activation/induction; red lines represent inhibition/repression. CREB, cAMP regulatory element-binding protein; eIF4B, eukaryotic translation initiation factor 4B; eIF4E, eukaryotic translation initiation factor 4E; Grb2, growth factor receptor-bound protein 2; JNK, c-Jun N-terminal kinase; Mnk1, MAPK-interacting protein kinase 1; mTORC1, mammalian target of rapamycin complex 1; Nrf2, nuclear factor erythroid 2-related factor 2; PGC-1a, peroxisome proliferator-activated receptor-g coactivator 1a; PGC-1b, peroxisome proliferator-activated receptor-g coactivator 1b; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; Ral, Ras-like; rpS6, ribosomal protein S6; RSK, p90RSK ribosomal S6 kinase; Shp2, nonreceptor tyrosine phosphatase with two Src homology 2 domains. [© 2018 Illustration Presentation ENDOCRINE SOCIETY].
with highest expression in the intervillus regions (). Little or no FGF is observed in the ileal crypts or lamina propria (). Of note, FGF expression in the ileum is weaker during gestation and lactation in mice and rats (-). In the pig intestine, expression of FGF begins soon after birth but achieves maximal expression in the ileum during adulthood ().
In the human fetus, in situ hybridization and RT-PCR analyses reveal FGF expression in brain, skin, cartilage, inner retina, small intestine, kidney, as well as placental villi and the umbilical cord (). FGF is also expressed in human embryonic stem cells, and expression levels correlate positively with the undifferentiated state (). In adulthood, FGF expression is detected in biopsies from human ileum, but not in biopsies from human colon (). FGF is not detected basally in human liver. Nevertheless, hepatic expression can be induced during cholestasis or cirrhosis (, ). Nonparenchymal cells, notably cholangiocytes (the cells lining the bile duct), largely contribute to FGF expression in the cholestatic liver (). Additionally, stimulated human hepatocytes also exhibit FGF induction in vitro (). Finally, FGF is also expressed in human gallbladder epithelial cells (, ). This expression appears even more abundant than in the ileum (, ).
In summary, whereas FGF expression is restricted to the distal part of the intestine in adult mice, gallbladder and cholestatic liver also express FGF in humans. A comparison of FGF and FGF expression patterns in mice and humans is illustrated in Fig. . FGF15/19 secretion FGF accumulates in a time-dependent manner in the media of cells infected with an FGF-expressing adenovirus, revealing the secretion of the protein (). However, FGF is a weak antigen, and detection of FGF in the blood has long been problematic, questioning its real endocrine action (). Initially, FGF was not detected in the rat portal circulation using mesenteric perfusion, suggesting a low level of production/secretion or a high lability of the protein (). Moreover, FGF protein levels in the portal blood do not match with the marked increase in FGF expression observed in the stimulated ileum (). Nevertheless, an assay by stable isotope standards and capture by an antipeptide antibodies assay, combining immunoenrichment with mass spectrometry, has overcome this issue (). This new dosage technique shows that () FGF circulates in plasma () in a regulated manner, () at concentrations that are known to activate its receptor, and () in strong correlation with ileal gene expression ().
Compared with FGF, immunological methods for detection (RIA-or ELISA-based assays) of FGF are more reliable, which has allowed the observation of a wide interindividual variation of concentration in human circulation (median  pg/mL, variation .-fold) (). Circulating FGF levels appear to be unrelated to age or sex in healthy humans (, ). However, other studies show that circulating FGF surges .-fold in early infancy from infra-adult to supra-adult concentrations (). However, this induction is reduced in small-for-gestational-age infants (). Surprisingly, centenarians also exhibit increased FGF levels, independently associated with their successful aging (). As FGF is mainly produced by the ileum, a primary delivery is expected in the portal circulation. In this way, portal levels of FGF are higher than arterial levels (). A net release of FGF by the portal-drained viscera can be calculated under fasted steady-state conditions, although no significant flux of FGF can be measured across the liver (). This suggests that most intestine-derived FGF binds to hepatocytes or the hepatic extracellular matrix during the first pass through the liver and does not substantially reach peripheral tissues, at least at the same concentration. Surprisingly, human bile contains -to -fold more FGF than does the systemic circulation (, ). The likely sources of biliary FGF are the gallbladder and the extrahepatic bile duct, both exhibiting high expression levels of FGF (, ).
In the gallbladder epithelium, FGF protein is present in cytoplasmic granules similar to secretory vesicles (). The role of this exocrine secretion is unknown and the impact of gallbladder-derived FGF on the circulating pool remains elusive. In fact, the lowering effect of bile acid (BA) sequestrants on serum FGF levels rather suggests a limited contribution of tissues other than the ileum ().
Regulation of FGF15/19 production

Molecular regulators
As with other endocrine FGFs, FGF/ is transcriptionally regulated by nuclear receptors. Farnesoid X receptor (FXR) is the classical nuclear receptor for BAs (, ). FGF is the most induced gene in human hepatocytes treated with the FXR synthetic agonist GW or the BA chenodeoxycholic acid (CDCA) (). The FGF gene contains functional FXR-responsive elements within the second intron () and in the promoter region (). Analogously, rat and mouse FGF genes contain FXR-responsive elements in intron  (), and FGF gene expression is dramatically increased in the intestine following GW administration (, ). Intestine-specific FXR-deficient mice show a strong downregulation of FGF expression in the ileum (), whereas transgenic mice expressing a constitutively active FXR in the intestine present an increased FGF expression in this tissue (). The FXR-mediated transcriptional activation of FGF is negatively regulated by sterol regulatory element binding protein (SREBP)- in human intestinal cells (). In turn, FGF increases functional interaction between SHP and SREBP-, leading to repression of SREBP- target genes ().
Pregnane X receptor (PXR) is another nuclear receptor whose primary function is to sense exogenous toxic substances, leading to the upregulation of detoxification proteins (). Highly hydrophobic BA, such as lithocholic acid (LCA), can also bind PXR (). Overexpression of PXR and stimulation with its ligand rifampicin lead to a significant activation of the proximal FGF promoter region in a human adenocarcinoma cell line (). In contrast, PXR appears to regulate negatively FGF expression in mice (). The promoter region of FGF also possesses a functional amino acid response element, responsible for enhancing transcription through activating transcription factor  in response to endoplasmic reticulum stress (). Induction of FGF is also observed after silencing release through blockade of cytosine guanine dinucleotide-binding domain proteins in HeLa cells (). Furthermore, FGF gene expression can be induced in colonic myofibroblasts through inhibition of miR- by carbon monoxide treatment ().
The FGF gene can also be repressed by transcription factors. Krüppel-like factor  (KLF) binds the FGF promoter at multiple consensus binding sites and represses FGF expression independently of BAs (). Overexpression of KLF in primary small intestinal epithelial mouse cells potently represses FGF gene expression, whereas knockdown of KLF induces FGF expression (). The transcription factor GATA represses FGF transcription within the proximal intestine and limits its expression to the ileum (). This inhibition occurs through both indirect mechanisms (modification of BA uptake and FXR gene expression) and direct binding to a consensus GATA regulatory element in intron  of the FGF gene ().
In addition to transcriptional regulation, FGF concentration seems to be controlled at the posttranscriptional level. Indeed, the protein Diet colocalizes and interacts with FGF to enhance its production levels via both transcriptional and posttranscriptional mechanisms (). Diet-deficient mice have reduced ileal FGF levels (). The regulation of FGF/ production in mice and humans, including transcriptional regulators involved, is summarized in Fig.  .
In addition to the direct regulation of its production, the action of FGF/ can be modulated through the tuning of its coreceptor KLB. In this way, FXR activation also primes the liver for FGF/ signaling through hepatic induction of KLB expression (). In contrast, miRNA-a inhibits KLB expression and attenuates hepatic responses to FGF (). In the same way, IL-b specifically inhibits KLB expression and FGF signaling in the liver () whereas TNF-a represses KLB expression in adipose cells (). Finally, as KLB is the obligate coreceptor for both FGF and FGF/, FGF overexpression antagonizes FGF/ binding to the KLB/FGFR receptor complex in mouse liver ().
BAs
As endogenous ligands for FXR, BAs are the prototypical inducers of FGF/. As a consequence, the modification of their concentrations and/or composition in the small intestine directly impacts FGF/ production. Four days of diet containing cholic acid (CA) increases FGF expression in the mouse ileum (). In contrast, administration of BA sequestrants (resins binding BA and preventing their reabsorption from the intestine) causes a steep decrease in ileal FGF gene expression in mice (, ). Of note, BA species have different impacts on the expression of FGF. Oral supplementation with CA or deoxycholic acid (DCA) increases the ileal expression of FGF at lower doses and to a higher extent than CDCA or LCA in mice (). Conversely, oral supplementation with ursodeoxycholic acid (UDCA) does not induce FGF expression in the ileum (). Coadministration of tauro (T)-bmuricholic acid (bMCA) attenuates T-CA-induced FGF expression in germ-free mice (), in line with the antagonist action of T-bMCA on FXR evidenced in this study. Nevertheless, the ability of orally administered BA to stimulate FGF in mice intestine only partially matches their agonistic activity on FXR (CDCA . DCA . LCA CA) (), possibly due to chemical conversion of the ingested BAs (as for example the bioconversion of CDCA into MCA in rodents). Moreover, beyond the specific ability of BA to activate the FXR receptor, transepithelial transport of BA is also a key step in the regulation of FGF/ production. Inhibiting apical vs basolateral BA transport in the ileum results in opposite regulation of FGF. In fact, FGF expression is strongly elevated in the ileum of mice deficient in the basolateral BA transporter organic solute transporter a (), whereas it is reduced in the ileum of mice deficient for the apical sodium-dependent BA transporter (, ).
In humans, both feeding () and intraduodenal infusion () of CDCA increase circulating FGF levels. Conversely, administration of UDCA to obese patients for  weeks reduces their circulating FGF levels (). Basal circulating FGF levels are also reduced following treatment with BA sequestrants in patients (, -). After cessation of treatment, FGF displays rebound increases above baseline levels (). In contrast, BA sequestrants in colonicrelease pellets fail to regulate FGF levels (). The selective ileal BA transporter inhibitor A decreases circulating FGF levels by % as soon as  hours after administration (). In human ileal explants, FGF expression is strongly induced by CDCA, glyco-CDCA, and CA, but DCA and LCA are significantly less potent (). In human primary hepatocytes, all BAs increase FGF gene expression, with the rank orders of FGF induction being CDCA ' CA . DCA ' LCA . UDCA (, ). The semisynthetic BA analog obeticholic acid also increases FGF secretion through FXR activation in human primary hepatocytes (, ) and in Caco- cells in which it is more potent than glyco-CDCA ().
Gut microbiota/antibiotics
The crosstalk between microbiota and the intestine wall, as well as the ability of gut microbiota to transform BA through various chemical processes (such as deconjugation and dehydroxylation), suggest that the gut microbiota can be a key player in the regulation of FGF/. This was first proven by the use of antibiotics. Administration of nonabsorbable antibiotic cocktails (ampicillin or bacitracin/ streptomycin/neomycin) significantly decreases FGF expression in mouse ileum (, ), in association with dampening of FXR signaling (). A compensatory increase in BA import and FGF expression can be observed in regions of the proximal small intestine in parallel with the decrease observed in the ileum following antibiotic exposure (). Antibiotic-mediated repression of the FGF gene can be prevented by supplementation with T-DCA or CA, but not with T-CA or bMCA (, ). This suggests that stimulation of FGF gene expression by gut microbiota is due to its ability to deconjugate T-CA into CA, which then adequately activates FXR signaling (). In line with this concept, FXR and FGF levels are higher in the ileum of conventionally raised mice compared with germ-free mice (). In turn, colonization of germ-free mice with mouse microbiota induces expression of FGF in their ileum whereas the induction is delayed after colonization with a human microbiota (). The microbiota-induced upregulation of FGF in the ileum is abolished in FXR-deficient mice ().
Moderate changes in gut microbiota through the administration of prebiotics or probiotics impact less consistently FGF expression in mice. Administration of the antioxidant tempol reduces the proportion of Lactobacillus (and its important bile salt hydrolase activity responsible for the deconjugation process). This leads to the accumulation of intestinal T-bMCA (an FXR antagonist) and reduction of FGF expression in mouse intestine (), corroborating studies using antibiotics. In contrast, supplementation with the VSL# probiotic (comprising several strains of Lactobacillus and Bifidobacterium) shifts gut microbiota and enhances BA deconjugation but represses ileal FGF expression (). Resveratrol administration, which enriches gut microbiota in Lactobacillus and Bifidobacterium, also decreases ileal FGF production (). Chronic ethanol treatment, associated with an overrepresentation of bacteria deconjugating BA and thus an increased amount of unconjugated BA in the intestine, dampens FGF secretion (). The supplementation with Lactobacillus rhamnosus in high-fat diet (HFD)-fed mice does not induce any change in intestinal FGF expression (). Taken together, these results suggest that the presence of gut microbiota is required for physiological BA deconjugation allowing a normal FGF expression. Nevertheless, enrichment of gut microbiota with species harboring a high BA deconjugating activity does not allow positive regulation of FGF. Finally, pathogenic bacteria can also regulate FGF. Indeed, infection with Salmonella or intravenous administration of Listeria both trigger a significant reduction in the intestinal expression of FGF, but surprisingly, this occurs independently of any damage to the ileal enterocyte layer ().
Macronutrients and micronutrients
Both chronic imbalance of diet composition in mice and acute administration of a single type of macronutrient in humans impact FGF/ production.
Consumption of an HFD stimulates FGF expression in mouse ileum (). Palmitic acid induces FGF gene expression in mouse ileum and also induces FGF expression in human hepatocytes (). Although the ingestion of lipids triggers BA release, the FGF secretion profile during a lipid tolerance test in humans remains uncertain (, ).
A sucrose-rich diet also induces the expression of FGF in mouse ileum (). In healthy humans, the ingestion of carbohydrates induces the most rapid and highest increase in circulating FGF levels compared with other macronutrients (). Because carbohydrate intake exerts little effect on global circulating BA levels, the underlying mechanism could be related either to a modification in BA composition (impacting FXR activation) or another pathway independent of the BA-FXR axis (). Nevertheless, neither glucose nor insulin seems to mediate the rise in FGF secretion because their postprandial levels were not associated with the FGF response (). The FGF increment after oral glucose loading is positively associated with age and negatively associated with abnormal glucose regulation (). The drop in circulating CDCA levels in patients with isolatedimpaired fasting glucose could explain their lower FGF secretion during a glucose tolerance test ().
FGF expression is not changed in the ileum of mice fed a leucine-deficient diet for  week (). Ileal FGF expression is increased in rats fed soy proteins compared with rats fed casein (). However, the addition of cholesterol to the soy protein diet is sufficient to repress FGF production (). In healthy humans, protein intake induces a modest and delayed elevation of FGF when compared with levels observed after carbohydrate ingestion ().
In a -month dose-response study evaluating undernutrition, only the most severe caloric restriction (% reduction of daily food intake) tends to increase FGF gene expression in the mouse ileum (). This upregulation appears to be caused by the increased intestinal BA content (in particular more hydrophobic BAs) (). In humans, few data regarding the impact of caloric restriction are available, but higher FGF levels are reported in children suffering from severe acute malnutrition ().
Fat-soluble vitamins stimulate both FGF and FGF transcription, but species differences are observed in terms of nuclear receptors involved in this process. In fact, receptors for vitamin A and D induce the expression of the FGF gene through distinct cis-acting response elements in the promoter and intron of the FGF gene. Transactivation of both response elements appears to be required to maintain basal FGF expression levels in vivo (). In mice, induction of FGF by vitamin D is mediated through vitamin D receptor independently of FXR, whereas the induction of FGF by vitamin A is mediated through the retinoid X receptor/FXR heterodimer, independently of BA (). In human intestinal cell lines, vitamin A derivatives induce FGF transcription (). In contrast to mouse FGF, this direct regulation is FXR-independent and mediated by retinoid X receptor/retinoic acid receptor heterodimer acting on a DR- element ().
Classically known to stimulate FGF production, the availability of inorganic phosphate (Pi) inversely impacts FGF production. In fact, dietary Pi restriction upregulates FGF expression in mouse ileum, but not in vitamin D receptor-deficient mice (). Conversely, high Pi-fed mice have significantly lower transcript levels of FGF in the ileum ().
Circadian rhythm
In mice, circadian analyses reveal the highest FGF expression in the ileum at the end of the dark phase (feeding period for rodents) and the lowest FGF expression at the end of the light phase (resting period for rodents) (, ). A strong correlation between ileal FGF expression and circulating FGF levels was observed across the day in mice (). Maximal ileal expression and circulating FGF levels were observed in the middle of the light phase in this study (). The transcription factor KLF is directly involved in the circadian control of FGF. In fact, KLF-deficient mice lose the daily pattern of FGF production with increased levels at multiple time points across a -hour cycle ().
The circadian pattern of FGF production driven by food consumption in mice is quite analogous to that observed for FGF in humans. In fact, circulating FGF levels exhibit a pronounced diurnal rhythm in humans, with peaks occurring  to  minutes after the postprandial rise in serum BA (). Moreover, the rhythmicity of circulating FGF is abolished upon fasting () and altered following cholecystectomy (), highlighting regulation by the transintestinal BA flux.
Intestinal/hepatic disease models The expression of FGF has also been investigated in the intestine of various mouse models mimicking human diseases of the digestive system. Ileal FGF expression is decreased in mice with dextran sulfate sodium-induced colitis (). This change is due to overactivation of the intestinal peroxisome proliferator-activated receptor (PPAR)a-uridine 9-diphosphate-glucuronosyltransferases axis, which promotes the metabolic elimination of BAs in enterocytes (). In contrast, dextran sulfate sodiumtreated mice with ileum-sparing colitis show higher circulating FGF levels (). IL--deficient mice with ileitis have a trend toward decreased circulating FGF levels compared with controls (). Mice suffering from colitis-associated cancer, exhibiting a concomitant decrease in FXR agonists and antagonists BAs in the ileum, have repressed FGF expression in the ileum (). Mice with acute cerulein-induced pancreatitis also exhibit a reduction of ileal FGF expression ().
Liver disease models also interfere with normal FGF expression in the gut. Mice with chemically induced cholestatic liver injury exhibit a reduction of FGF expression in the ileum (). In contrast, hypercholanemic organic anion-transporting polypeptide-deficient mice and sodium taurocholate cotransporting polypeptide-deficient mice present increased FGF expression, in line with observations in mice treated with a specific sodium taurocholate cotransporting polypeptide inhibitor (). Mice overexpressing the bile salt export pump (ABCB) also show strongly elevated FGF expression levels in the ileum (). Mice with hepatocyte-specific expression of a dominant stable form of b-catenin exhibit severe cholestasis and high ileal FGF expression levels ().
Surgical procedures
Bariatric surgeries, such as Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy, and gastric banding, cause substantial weight loss and are now popular treatments for obesity (-). Beyond the decrease in body weight, these surgical procedures induce substantive metabolic changes, notably affecting FGF/ levels.
Gastric banding consists of the placement of a silicone ring around the stomach to create a small upper gastric pouch at the bottom of the esophagus (-). An initial report showed no significant change for basal circulating FGF levels after gastric banding compared with preoperative values (), whereas more recent studies report a decrease () or a continuous increase (). Postprandial circulating FGF concentration increases after laparoscopic adjustable gastric banding ().
In the RYGB, a small gastric pouch is created, draining alimentary bolus into the jejunum (alimentary limb), which causes nutrients to bypass the pylorus and duodenum (). Early and late observations after RYGB surgery reveal that fasting circulating levels of FGF are elevated compared with preoperative values (, -). Circulating FGF levels also increase after biliopancreatic diversion () and after implantation of a duodenojejunal bypass liner excluding the duodenum and proximal jejunum from contact with ingested food (). The rise in FGF seems directly related to the surgery because no change is observed in subjects who achieve similar improvements in glycemic control () or weight loss () by conventional dietary treatment. The postprandial peak of FGF also occurs earlier and reaches a higher value in RYGB patients (, ). Nevertheless, other studies show no change in fasting FGF levels acutely or until  year after RYGB (), or report nonsignificant trends of increased FGF levels from presurgery to  years postsurgery (). One possibility is that surgery can change FGF levels in only some patient subsets. In fact, no change in circulating FGF levels is detected in RYGB patients exhibiting normal preoperative glucose tolerance, whereas low levels of FGF observed in diabetic patients gradually increase after RYGB surgery ().
Sleeve gastrectomy consists of the creation of a long, thin, longitudinal gastric pouch or sleeve, reducing the volume of the stomach by~% to %, but leaving the pylorus intact (). Fasting and postprandial FGF levels increase after sleeve gastrectomy (-), possibly in line with changes in BA composition observed after this surgical procedure (). Circulating FGF also increases after laparoscopic greater curvature plication ().
Surgical procedures also regulate FGF in rodents. In mice, ileocecal resection leads to the upregulation of FGF expression in the ascending colon, but this compensation is absent in germ-free mice and in FXRdeficient mice (). After bile flow diversion through gallbladder anastomosis to the ileum, FGF gene expression is repressed more than twofold in the ileum, despite a massive increase in circulating BAs (mainly the FXR antagonist T-bMCA and T-vMCA) (). Repopulation of mouse liver with human hepatocytes strongly induces FGF expression in the ileum (). In rats, ileal interposition (surgical relocation of the distal ileum into the proximal jejunum) causes a robust induction of FGF (). Vagotomy changes BA composition and increases passive absorption of BAs leading to induction of FGF in the rat intestine ().
Role of FGF15/19 in Development and Cellular Growth/Proliferation
Effects on fetal tissues Several members of the FGF family act in the early stages of embryonic development and during organogenesis to maintain progenitor cells and mediate their growth, differentiation, survival, and patterning (). In addition to its endocrine functions, FGF/ is also involved in numerous developmental processes, mainly evidenced in the chick, zebrafish, or mouse embryo. Survival of mice deficient in FGF depends on the genetic background. Under the CBL/ //Sv hybrid background, FGF knockout (KO) mice are mostly embryonic lethal, because ,% of the homozygous mice can survive (). In contrast, under a SvJ background, FGF KO mice are viable and fertile ().
Otic development
From the earliest stages of development, the FGF gene is expressed in anatomic regions involved in inner ear development in the chick (). As a mediator of the mesodermal signal, FGF synergistically interacts with Wnt-c (mediating neural signals) to initiate inner ear development (). The FGF gene is induced in the mesoderm by FGF originating from the endoderm, and, in turn, FGF stimulates neural ectoderm to express signals promoting the otic placode (). FGF signaling is required to initiate a proliferative progenitor region that is a precursor of both the inner ear and the neurogenic epibranchial placodes ().
Mouse FGF KO embryos do not have otic abnormalities at E. to E. (). Unlike FGF, FGF is not expressed in the mesoderm underlying the presumptive otic placode, but is expressed in the adjacent neurectoderm (). This suggests that during otic induction, FGF signals in either an autocrine fashion to the mesoderm or a paracrine fashion to the neurectoderm, whereas FGF signals in an autocrine fashion to the neurectoderm ().
Eye development
In the developing chick, FGF is expressed in the retina, optic vesicle, lens primordia, retinal horizontal cells (), and, more acutely, in the postmitotic neuroblasts during their migration from the ventricular surface to their final location (). During the last third of embryogenesis, FGF expression in the retina is progressively downregulated and is no longer detected at  month of life (). FGF/FGFR signaling interplays with FGF signaling and the L-Maf transcriptional system to regulate early lens development ().
In zebrafish embryos, the transcription factor forkhead box C induces FGF expression in corneal and periocular mesenchymal cells (). Loss of FGF results in anterior segment structures within the eye () and a size reduction of the lens and the retina (). FGF is involved in cell survival but not in cell proliferation during embryonic lens and retina development ().
In the pig, FGF is expressed in adult retinal pigment epithelial cells and impacts proliferation/ survival in photoreceptors (). In mice, FGF is also expressed in the optic vesicle, a subset of progenitor cells of the neural retina, emerging ganglion, and amacrine cells during retinogenesis ().
Brain development
In the zebrafish, FGF is expressed in the forebrain, midbrain, and hindbrain and is involved in cell "Beyond the decrease in body weight, these surgical procedures induce substantial changes, notably affecting FGF15/19 levels." proliferation and cell survival during embryonic brain development (). FGF appears essential for the specification of g-aminobutyric acidergic interneurons and oligodendrocytes generated in the ventral telencephalon and diencephalon (). In the forebrain, FGF expression is downregulated on inhibition of hedgehog signaling ().
In mice, FGF is expressed from early neurulation in various zones of the neural tube, including the isthmus, the intrathalamic zona limitans, and the anterior neural ridge (). FGF is initially present in domains where FGF is also expressed and, at later stages, in specific groups of neural cells (). In the diencephalon and midbrain, FGF regulates proliferation and survival of dorsal cell populations by regulating the ability of dorsal neural precursors to respond to dorsally secreted Wnt mitogens (). FGF is directly regulated by sonic hedgehog signaling through the GLI zinc finger transcription factors (, ). Studies using FGF KO mice reveal that FGF suppresses proliferation and promotes neuronal differentiation and caudoventral fate (), showing opposite effects to FGF on neocortical patterning and differentiation. In FGF KO mice, dorsal midbrain neural progenitors fail to exit the cell cycle and to generate the requisite number of postmitotic neurons due to altered expression of differentiation helix-loop-helix transcription factors (). In fact, the expression of Id, Id, and Hes is strongly increased and ectopically expanded, whereas the expression of Ascl, Neurog, Neurog, and Neurod is strongly decreased in the dorsolateral midbrain of FGF KO mice compared with wild-type mice (). Moreover, FGF KO embryos exhibit a strong reduction of FGFR expression in the alar prethalamus, associated to a high proliferation rate of thalamic progenitors and disruption of thalamic neurogenesis (). FGF is a direct target of miR- in the fetal neural tube, and FGF overexpression is sufficient to drive precocious neural differentiation (, ).
In humans, FGF could also harbor morphogenic properties in the brain, as suggested by its ability to promote spontaneous generation of dorsoventrally polarized neural tube-like structures at the level of the cerebellum in tridimensional embryonic stem cell culture ().
Heart development
In mice, FGF is detected in the developing pharyngeal arches, a region important for correct development of the aortic arch and cardiac outflow tract (). FGF KO mice present early morphological abnormalities of the outflow tract due to aberrant behavior of the cardiac neural crest, resulting in heart defects consistent with misalignment of the aorta and pulmonary trunk (). In this context, FGF operates through a pathway independent of Tbx, a master regulator of pharyngeal arches development (). Homology in the enhancers of the FGF and FGF promoters suggests that FGF is also involved in the early development and distribution of cardiac neural crest cells, being a candidate gene for congenital heart defects in humans ().
Effect on hepatocyte growth and proliferation
The first evidence of a role for FGF in hepatocyte growth came from phenotypic observations in FGF transgenic mice who developed locally invasive HCC tumors by  to  months of age (). Hepatocellular proliferation, predominantly observed in pericentral hepatocytes, precedes tumor development (). Similarly, acute FGF administration also increases hepatocellular proliferation (). Furthermore, FGF delivery through adeno-associated virus (AAV) induces highly proliferative liver tumors with a latency depending on the mouse genetic background (). Hepatocarcinogenesis in FGF transgenic mice can be prevented by monoclonal antibodies selectively blocking the interaction of FGF with FGFR () or by genetic FGFR deficiency (). These results strongly suggest that FGFR mediates the oncogenic effect of supraphysiologic levels of FGF. In agreement, molecular studies with truncated mutants of FGF and with FGF/FGF chimeric molecules also identify the FGF-FGFR interaction as the mechanism driving hepatocyte proliferation and HCC (, ).
Additional studies revealed the molecular and cellular mechanisms underlying FGF-induced oncogenicity. In vivo, as soon as  hours after a single administration of FGF, the expression of key proteins known to drive cell proliferation (such as TGFb-induced protein ig-h, vascular cell adhesion molecule , annexin A, and vigilin) are induced in mouse liver (). In vitro, FGF induces the expression of the epidermal growth factor receptor ligand amphiregulin, which participates in the induction of the cycle cell regulator cyclin D (). FGF increases the invasive capabilities of human HCC cell lines by promoting epithelial-mesenchymal transition via a GSKb-b-catenin pathway (, ).
Moreover, FGF facilitates cell survival through a resistance to apoptosis, involving GSKb activation and nuclear accumulation of nuclear factor erythroid -related factor  (). FGF increases the STAT protein level and its phosphorylation (). This action is central to the proliferative properties of FGF. In fact, a modified FGF unable to induce STAT phosphorylation presents no mitogenicity and no induction of pro-oncogenic target genes (). In contrast to FGF, long-term overexpression of FGF does not induce HCC in db/db and dietinduced obese (DIO) rodent models (). Again, this is also due to the absence of upregulation of STAT target genes in livers of mice overexpressing FGF (). The hepatocellular ablation of STAT blocks the initiation and progression of FGF-dependent HCC formation (). In vivo and in vitro observations suggest a non-cell-autonomous activation of STAT by FGF () and identify IL- originating from immune/Kupffer cells as a key intermediate relaying the protumorigenic activity of FGF in mice ().
Several therapeutic approaches have been used to dampen the oncogenic FGF-FGFR signaling pathway. Functionally, clonal growth and tumorigenicity of HCC cells can be inhibited by knockdown of FGF through RNA interference, small hairpin RNA, or neutralizing anti-FGF antibodies (, ). Anti-FGFR monoclonal antibody inhibits tumor growth in mice bearing the HUH liver cancer cell line xenograft (). BLU, a selective and irreversible smallmolecule inhibitor of FGFR, shows antitumor activity in mice with an HCC tumor overexpressing FGF (). The selective covalent FGFR inhibitor, HB-, tested in a large panel of HCC cell lines and patient-derived xenografted mouse models shows that FGF expression is a predictive biomarker for its response (). Cancer cell lines harboring a gain of FGF copy number and a concomitant expression of KLB are sensitive to the selective FGFR inhibitor NVP-BGJ (). ASP, an inhibitor of FGFR-, potently suppresses the growth of several FGF-expressing hepatocellular carcinoma cell lines and induces sustained tumor regression in xenografted mouse models (). Nevertheless, the strategy of inhibiting the FGF-FGFR pathway in HCC carries intrinsic safety risks. This represents a translational challenge with questions about the degree of blockade to achieve therapeutic benefits without inducing adverse hepatic/gastrointestinal toxicity in humans (). Anti-FGF antibody demonstrated dose-related liver toxicity and severe diarrhea in a safety study in cynomolgus monkeys (). The side effects seem to be related to increased BA synthesis, change in the expression of BA transporters in the liver and ileum, and enhanced BA enterohepatic recirculation ().
The blockade of elevated FGF levels or the inhibition of overactivated FGFR signaling could present valuable antioncogenic properties. Nevertheless, FGF/ signaling can stimulate liver regeneration in case of increased demand. FGF administration promotes liver repair in mouse models of chemical liver injury or partial hepatectomy (), even improving survival after extensive hepatectomy (). An FGF/apolipoprotein A-I chimeric molecule reduces liver injury and enhances regeneration in acetaminophen-intoxicated or hepatectomized mice (). Conversely, the lack of endogenous FGF can also be deleterious in situations of regenerative need. FGF KO mice have extensive liver necrosis due to reduced hepatocyte proliferation and impaired cell cycle progression (). After administration of carcinogens, FGF KO mice present attenuated hepatocellular proliferation and fibrogenesis compared with wild-type mice (). FGF KO mice show more advanced liver injury (and mortality depending on genetic background) following partial hepatectomy (, ) or acetaminophen overdose (). Of note, even if the downregulation of FGF/ -FGFR signaling can directly dampen hepatocyte regeneration, it can also have deleterious consequences for liver integrity through derepressed BA synthesis. Thus, liver alterations in FGF KO mice are accompanied by persistently elevated intrahepatic BA levels (). Short interfering RNA-mediated knockdown of FGFR also causes necrotic damage due to intrahepatic overload of BAs (in particular of T-CA) following partial hepatectomy (). Accumulation of BA in the liver in the context of FGF/ FGFR inhibition could result from an imbalance between constitutive BA overproduction exceeding export capabilities. Another explanation could be a change in BA transporters that are tightly controlled by hepatic FXR activity, itself dependent on BA composition.
Progression of liver HCC caused by FXR deficiency can be prevented by the reactivation of intestinal FXR, normalizing the FGF axis and BA homeostasis (). As for FGF/, BAs are also key players of the hepatostat (adjustment of liver size to the physiological need) (), delineating direct and indirect (BAmediated) actions of FGF/. In this way, enhanced growth of livers of mice with humanized hepatocytes, which do not recognize FGF, is due mainly to increased BA synthesis (). Nevertheless, mice overexpressing FGF present very low BA levels but show increased hepatocyte proliferation in basal conditions and a further induction of cell-cycle progression genes after partial hepatectomy (). This demonstrates that FGF is critical in the phases of priming and termination of liver regeneration, independently of BA levels ().
Effect on skeletal muscle growth FGF signaling is an important regulator of myogenesis (-), but the involvement of endocrine FGFs in this process was long unrecognized. A recent report revealed a role for FGF in the regulation of skeletal muscle mass (). Treatment with FGF causes skeletal muscle hypertrophy in mice leading to a better muscle strength (). Hypertrophy is not related to the numbers or the type of muscle fibers, but to a shift toward larger myofibers (). In human myoblasts, FGF does not affect cell proliferation or the expression of classical myogenic factors, but it increases the size of myotubes (). Muscular signaling in response to FGF stimulation includes the phosphorylation of ERK/ and the ribosomal protein S kinase (). Interestingly, FGF ameliorates skeletal muscle atrophy in obese and aged mice as well as in mice treated with glucocorticoids (), and therefore "Several therapeutic approaches have been used to dampen the oncogenic FGF19-FGFR4 signaling pathway." represents a promising strategy for increasing skeletal muscle mass in various human pathological conditions. Of note, FGF is devoid of muscular anabolic action, and muscle-specific KLB-deficient mice are refractory to the hypertrophic effect of FGF (). Thus, FGF should act through the KLB-FGFR complex in skeletal muscle, in line with previous reports involving FGFR in myogenesis (-).
Role of FGF15/19 in Metabolism
Effect on liver and gallbladder
BA homeostasis
BAs are amphiphatic molecules produced by the liver from cholesterol through two distinct synthesis pathways. In the classic (neutral) pathway, cholesterol a-hydroxylase (CYPA) is the rate-limiting and major regulatory enzyme (, ). Later steps involve sterol a-hydroxylase leading to synthesis of CA whereas other enzymes can alternately produce CDCA (, ). In the alternative (acidic) pathway, cholesterol is only converted to CDCA (, ). CDCA is more hydrophobic than CA but is rapidly metabolized into highly hydrophilic MCAs in rodents, but not in humans (, ). All the primary (liverderived) BAs are conjugated with taurine or glycine to enhance their solubility and represent the main organic compounds of bile, secreted by the liver into the gallbladder for interprandial storage (, ). Meal consumption triggers the release of bile into the duodenum to allow emulsification and digestion of dietary lipids. BAs are actively reabsorbed in the ileum, and they return to the liver through the portal circulation, thus following an enterohepatic circulation (, ). The few primary BAs escaping active ileal reuptake reach the colon and are metabolized by gut microbiota into secondary BAs (for example by dehydroxylation of CA into DCA), which are passively absorbed by the colon or eliminated in the feces (, ). Beyond their role in lipid assimilation, BAs have hormonal actions throughout the body. Notably, BAs bind and activate several receptors, mainly nuclear FXR and membrane TGR (G-protein coupled BA receptor ) BA receptors, both central regulators of glucose and lipid homeostasis (, ).
As biological detergents, BAs can be toxic and their production needs to be tightly regulated. In the hepatocyte, FXR acts as the main BA sensor in charge of a negative feedback, limiting BA production (, ). Thus, CYPA is overexpressed in FXR-deficient mice (). A series of experiments has revealed that FGF is central in the control of BA production. FGF expression is strongly induced by BA in human hepatocytes and, in turn, treatment with FGF reduces the level of CYPA expression (, ). In the same way, mice overexpressing FGF present low CYPA expression and reduced BA production (, ). These observations initially suggested a hepatic autocrine/paracrine role for FGF in the repression of BA production. Similarly, FGF is also involved in the negative feedback of BA synthesis. FGF administration decreases CYPA mRNA levels in wildtype but not in FGFR KO mice (). Both FGF KO, FGFR KO, and KLB KO mice present elevated BA production due to upregulation of CYPA in the liver (, -). Further studies have highlighted the central role of the intestine in the negative feedback model. Notably, ileal FGF expression negatively correlates with hepatic CYPA expression in bile duct-ligated mice (). Moreover, the FXR agonist GW significantly represses hepatic CYPA expression in liver-specific FXR-deficient mice, but not in intestine-specific FXR-deficient mice (). This demonstrates that activation of FXR in the ileum, and subsequent FGF release, is required for short-term CYPA repression. Of note, sterol a-hydroxylase expression is more dependent on direct negative feedback by hepatic FXR than intestinal FXR-FGF/  (, ). The role of FGF in the ileohepatic negative feedback of BA synthesis is also supported by clinical observations. A postprandial increase in BA levels triggers FGF secretion, which is followed by a decrease in BA synthesis (). Moreover, both primary BA malabsorption () and ileal resection () reduce FGF levels and increase BA synthesis.
Beyond the regulation of the global level of BA production, ileohepatic FGF/-FGFR-KLB negative feedback also impacts BA composition. FGF infusion in mice shifts BA synthesis from the neutral to the alternative pathway, reducing the CA/CDCA ratio (). Analogously, FGF injections increase the MCA/CA ratio in mouse bile, inducing a more hydrophilic BA pool (). Treatment with the intestinal FXR agonist fexaramine induces enteric FGF and leads to increases in LCA (a secondary BA derived from CDCA), at the expense of T-CA (, ). Nevertheless, this latter observation requires further confirmation because substantial amounts of LCA in mouse plasma are not reported in others studies (, , , -).
On the contrary, mice with intestinal FXR deficiency exhibit very low FGF expression levels, an increased proportion of CA and DCA, and a decreased proportion of b-MCA and v-MCA in bile (). This leads to a rise in the BA hydrophobicity index compared with wild-type mice (). Mice with hepatocytespecific KLB deficiency exhibit an increased fraction of CA in their BA pool (). In the same way, global KLB KO mice exhibit a shift in BA production (). This modification is highlighted by activation of the classical BA synthesis pathway at the expense of the alternative pathway (). This leads to a predominant representation of CA and DCA among circulating BAs (). Similarly, in humans, BA sequestrants decrease FGF levels and result in a preferential increase in CA synthesis at the expense of CDCA (). Taken together, these observations show that FGF/ negative feedback shifts BA synthesis from the neutral to the alternative BA synthesis pathway, both in mice and humans. In rodents, this results in a more hydrophilic BA pool due to the conversion of hydrophobic CDCA into highly hydrophilic MCA. In contrast, in humans, this generates a more hydrophobic BA pool. Conversely, attenuation/abrogation of FGF/ signaling enriches the BA pool in a-hydroxylated BAs such as CA or DCA. This results in a relatively more hydrophobic BA pool in rodents and a more hydrophilic BA pool in humans (with CA being more hydrophilic than the persistent CDCA). As a consequence, FGF/  signaling can change not only BA levels, but also BA species distribution. Therefore, modification in the composition of the BA pool also impacts the intracellular signaling through the BA receptors FXR and TGR.
As a gatekeeper of BA production, FGF can represent a therapeutic opportunity to treat diseases related to BA dysregulation. However, the proliferative action of FGF on hepatocytes represents a major risk to treating hepatobiliary disorders. To overcome this therapeutic limitation, molecular reengineering of the FGF molecule allows dissociation of the proliferative and metabolic properties of the molecule. The genetically modified FGF M carries three amino acid substitutions (AS, GS, and HL) and a five-amino acid deletion. This FGF variant exhibits the same biological activity as FGF, including FGFR binding, ERK signaling, and suppression of CYPA, without tumorigenicity (). M protects mice from liver injury induced by either extrahepatic or intrahepatic cholestasis (, ). AAV-mediated delivery of M rapidly attenuates liver injury, inflammation, biliary fibrosis, and cholelithiasis in mice deficient for the canalicular phospholipid flippase (MDR KO mice) (). The hepatosplenomegaly and ductular proliferation associated with cholangiopathy are also improved with M administration (). From a translational point of view, M potently reduces circulating levels of a-hydroxy--cholesten--one in healthy volunteers (). This reflects a dampening of CYPA activity in humans with the perspective of treating disorders of BA dysregulation (). To date, M (also named NGM) is the only FGF analog tested in clinical trials in patients suffering from primary biliary cirrhosis and diabetes ().
Gallbladder filling Another main function of FGF/ in BA homeostasis relates to the filling of the gallbladder. The gallbladder of the FGF KO mouse is almost devoid of bile, and administration of FGF or FGF causes a .-fold increase in gallbladder volume, without changing bile flow rate (). A weaker stimulatory action of FGF/ in the filling of gallbladder is also observed in wild-type mice (). As no FGF expression is detected in the liver, gallbladder, common bile duct, or sphincter of Oddi, this suggests that ileal-derived FGF acts as a hormone to stimulate gallbladder filling in mice (). The gallbladder volume is also reduced in FGFR KO mice but to a lesser extent than in FGF KO mice, suggesting that other FGFRs contribute to the actions of FGF on the gallbladder (). In the same way, gallbladder volume is reduced in KLB KO mice, which exhibit a resistance to gallstone formation (). Postprandial circulating cholecystokinin concentrations are lower in FGF KO mice compared with wild-type mice, demonstrating that this classic bile-releasing factor is not involved in the action of FGF (). In contrast, FGF completely blocks contraction of the gallbladder caused by cholecystokinin (). FGF and FGF stimulate gallbladder filling at least in part by causing a cAMP-dependent relaxation of gallbladder smooth muscle (). In humans, after CDCA administration, a progressive increase over time in both FGF levels and gallbladder volume is observed both in control subjects and in patients with intestinal diseases ().
The high concentration of FGF in human bile (, ), originating from the gallbladder itself and the extrahepatic bile duct (, ), contrasts with the absence of FGF in mouse bile. The role of this exocrine secretion remains poorly studied. It has been suggested that biliary FGF can protect against detrimental effects of BAs or regulate mucin expression in tissues exposed to concentrated bile (). This action can explain species differences because mice, devoid of biliary FGF, have a less toxic/hydrophobic BA composition than do humans.
Nutrient partitioning in postprandial and fasted states
In response to BA and nutrients reaching the intestine during digestion, FGF gene expression gradually increases in the mouse ileum, peaking around  hour postgavage (). In humans, circulating FGF concentration peaks  to  hours following a meal (, ), with an approximate half-life of  minutes (). This food-driven pattern of regulation suggests that FGF/ can act as a hormone of the fed state. In fact, administration of FGF significantly increases protein synthesis and glycogen accumulation in the liver of fasted mice (). In contrast, fed FGF KO mice have half the hepatic glycogen stores compared with wild-type mice (). This effect of FGF/ is similar to, but independent of, insulin action. In fact, postprandial peak of FGF levels is delayed compared with the insulin peak (). Additionally, insulin increases hepatic FGFR levels (), suggesting a priming of FGF action. Both hormones work in a "FGF19 can represent a therapeutic opportunity to treat diseases related to BA dysregulation." coordinated, temporal fashion to facilitate the proper storage of nutrients after a meal (). Even if FGF signaling decreases FoxO activity, as does insulin (), the intracellular signaling pathways used by FGF and insulin show differences. FGF activates the Ras/ ERK/MAPK-interacting protein kinase /pRSK pathway, whereas insulin signals through phosphatidylinositol -kinase/Akt/mTOR/pSK, allowing overlapping but distinct biological actions for both hormones ().
Unlike insulin, FGF does not acutely increase hepatic triglycerides in the postprandial state, thus uncoupling carbohydrate and lipid storage (). Furthermore, in rat primary hepatocytes, FGF suppresses the expression of lipogenic enzymes and represses the insulin lipogenic action (through increasing STAT activity and decreasing PPAR-g coactivator b expression) (). In fasted mice, injection of FGF decreases the expression of proteins involved in fatty acid synthesis and increases the expression of proteins involved in fatty acid oxidation (). FGF/ also inhibits the expression of onecarbon cycle genes, critical determinants of hepatic lipid levels (), and mediates postprandial epigenetic repression of hepatic autophagy ().
In addition to its action during the fed state, FGF/ suppresses hepatic metabolic pathways, which are active during fasting, including gluconeogenesis and the tricarboxylic acid cycle flux (). This hepatic action is mediated through decrease of the activity of transcription factor cAMP regulatory element-binding protein and downregulation of PPAR-g coactivator a and its gluconeogenic/ oxidative target genes (). In agreement, FGF KO mice and FGFR KO mice exhibit increased gluconeogenesis and higher glycemia than do wildtype mice after refeeding ().
Hepatic lipid storage
The concomitant role of FGF/ in the control of BA production and nutrient partitioning raises questions about its long-term effects on hepatic lipid metabolism. FGF transgenic mice present a reduced expression of lipogenic enzymes and triglyceride content in the liver (). Treatment with the longlasting FGF/apolipoprotein A-I chimeric molecule also reduces liver lipid accumulation in vivo and protects hepatocytes against endoplasmic reticulum stress and cytotoxicity induced by palmitic acid in vitro (). In mice fed a high-fat, high-fructose, highcholesterol diet, reengineered FGF M reduces hepatic levels of toxic lipid species (diacylglycerols, ceramides, and free cholesterol) and increases levels of unoxidized mitochondrial cardiolipins (). In line with a FGF/-mediated repression of liver fat storage, FGF KO mice also exhibit exacerbated hepatic steatosis when fed an HFD () although other studies only report an attenuation of fibrosis in the same context (). Of note,  to  weeks of FGF administration transiently increase circulating triglycerides and cholesterol levels in ob/ob mice and in DIO mice (). This action is also observed with a modified FGF (), only activating FGFR, and could be directly related to the inhibition of BA production. In fact, treatment with BA binding resins (, ), as well as CYPA deficiency (), increases triglyceride levels. However, this effect remains transitory, suggesting that it is gradually overcome by the more chronic extrahepatic lipid-lowering action of FGF ().
Taken together, these results suggest that activation of the FGF/ signaling pathway present potential opportunities with respect to hepatic steatosis. Nevertheless, the abrogation of endogenous FGF signaling does not result in an inverse hepatic fat overload. In fact, both FGFR KO mice and KLB KO mice exhibit few modifications of hepatic lipid content on a chow diet, and they are resistant to hepatic steatosis on an HFD (, , , ). A possible explanation for this protection can be the modification in BA levels/composition. In fact, mice overexpressing CYPA present a similar pattern of BAs as do KLB KO mice and exhibit the same resistance to hepatic steatosis (). The underlying mechanisms could involve changes in FXR signaling in the liver [known to repress de novo lipogenesis ()] or activation of TGR signaling in BAT (driving thermogenic lipid use) (). Thus, if FGF/ signaling presents direct antilipogenic actions in the long-term, its blockade also leads to attenuation of hepatic lipid storage through the modification of the BA pool. Of note, FGF can also interfere with the secretory function of the liver, regulating the expression of its sister molecule FGF (), as well as antiatherogenic and atherogenic proteins (-).
Effect on whole-body energy and glucose homeostasis Several genetic and pharmacological studies in mice have demonstrated the beneficial action of FGF/ in energy balance. Transgenic mice overexpressing FGF are leaner than wild-type mice, exhibiting decreased fat content despite higher food intake (). This phenotype is explained by higher oxygen consumption (with no change in the respiratory quotient, reflecting the proportion of carbohydrates and lipids used) and is also associated with an increased insulin sensitivity (). FGF overexpression also confers resistance to DIO and can alleviate the genetic obesity in ob/ob mice, partly due to the increase in BAT activity (). AAV delivery of FGF and FGF also allows investigation of their global metabolic actions. Both FGF and FGF overexpression reduce fat mass and increase energy expenditure in DIO mice, but FGF appears more potent (). FGF overexpression, but not FGF overexpression, reverses diabetes in db/db mice (independently of weight loss) (). Moreover, endogenous FGF does not influence body weight homeostasis through extrahepatic action. In fact, hepatocyte-specific KLB KO mice present high FGF levels but gain similar weight to wild-type mice on an HFD (). As with genetic overexpression, short-term ( week) pharmacologic administration of FGF exerts systemic metabolic actions. IV administration of FGF ( mg/kg) increases the metabolic rate and fat oxidation in mice on an HFD, without modifying food intake (). Treatment with IP FGF ( mg/kg) reduces body weight and enhances glucose utilization in both DIO and ob/ob mice (, ). The improved glycemia obtained through subcutaneous FGF infusion ( mg/kg) occurs independently of any change in body weight in ob/ob mice ().
Taken together, these metabolic observations suggest that FGF represents an interesting candidate for treatment of obesity and TD. Modified forms of FGF have also dissociated its effects on lipid and glucose metabolism. FGF (FGF-) retains the ability to stimulate glucose uptake in vitro and in vivo in ob/ob mice without inducing FGFR-mediated hepatocyte proliferation (). FGFv, which activates KLB/FGFRc, but not KLB/FGFR, reduces blood glucose levels and therefore improves glucose tolerance (). Similarly, FGF-, presenting a preferred selectivity for FGFRc, is equally effective as wild-type FGF in regulating glucose, lipid, and energy metabolism in DIO and ob/ob mice (). In contrast, FGFdCTD, which activates only FGFR, but not FGFRc, FGFRc, or FGFRc, represses BA synthesis, but it fails to improve glucose levels and insulin sensitivity in ob/ob mice (). Moreover, infusion of FGF at supraphysiological levels improves glucose tolerance (independently of body weight) to a similar extent in wild-type and FGFR KO mice, indicating that FGFR is not required for glucose lowering (). Taken together, these results demonstrate that in contrast to the repression of BA synthesis mediated through FGFR, the glucose lowering action of (pharmacologic) FGF is mediated by FGFR. Other studies revealed that the glucose lowering action of FGF involves FGFR expression, not in the adipose tissue (), but rather in the central nervous system ().
Effect on brain impacting body energy and glucose homeostasis Numerous gut-derived hormones act on the central nervous system to elicit their metabolic effects, including the control of food intake, energy expenditure, and glucose tolerance (, ). This suggests a possible involvement of FGF/ in the metabolic gut-brain axis. In contrast to specific uptake of FGF in the liver, influx of FGF into mouse brain is nonlinear, nonsaturable, and affected by its blood concentration (). Peripheral delivery of FGF triggers ERK signaling in the hypothalamus (). FGFR and FGFR are both present in rat hypothalamus (). KLB is also expressed in the mouse hypothalamus (in particular in the suprachiasmatic and paraventricular nuclei), in the hindbrain (in the area postrema and the solitary nucleus), and in the nodose ganglia of the periphery (, ). Taken together, these nuclei expressing KLB include the dorsal-vagal complex, a major integrative center for the autonomic nervous system (). Although of primary interest, these observations in murine studies require caution regarding their translation to humans.
The first evidence of a brain-mediated FGF metabolic activity comes from central injections of FGF into the lateral ventricle in mice, which produce an increase in the metabolic rate comparable to systemic administration (). This observation is confirmed by central FGF delivery, which stimulates sympathetic outflow to BAT and increases energy expenditure (). Moreover, studies involving genetically modified mice also support a central action for FGF. In fact, mice harboring KLB deficiency in the central nervous system are refractory to body weight and glycemia improvements induced by FGF, whereas mice with hepatocyte-or adiposespecific KLB deficiency remain sensitive to FGF action ().
Mechanistically, some studies suggest that central FGF/ signaling interferes with neuronal control of insulin and glucagon secretion, whereas other studies highlight a role in the hypothalamic-pituitary-adrenal axis or glucose effectiveness (insulino-independent glucose use).
Intracerebroventricular (ICV) FGF injections for  days reduce body weight and improve both glucose-induced insulin secretion and insulin sensitivity in DIO mice (). This involves activation of ERK/ signaling and repression of agouti-related protein/ neuropeptide Y (NPY) neuron activity (). Thus, FGF/ partially recapitulates the central action of leptin. Recent insights also suggest that hypothalamic FGF/ signaling can be antagonized by paracrine FGF produced within the hypothalamus (). Moreover, acute FGF administration into the third cerebral ventricle in rats reduces daily food intake and body weight, and acutely improves glucose tolerance (). Conversely, administration of an FGFR- antagonist increases food intake and impairs glucose tolerance (). It involves transient sympathoadrenal activation and a reduction of insulin secretion (). Another role for central FGF has recently emerged in glucose counterregulation. ICV injections of FGF reduce the neuroglucopenia-induced activation of the dorsal vagal complex neurons and the "Transgenic mice overexpressing FGF19 are leaner than wild-type mice." parasympathetic nerve, thus lowering glucagon secretion (). Alternatively, silencing FGF expression in the dorsomedial hypothalamus increases neuroglucopenia-induced glucagon secretion ().
A single, low-dose ICV injection of FGF improves glucose intolerance within  hours in ob/ ob mice, independently of changes in energy balance (). This direct antidiabetic action is due to increased peripheral glycolysis and is independent of changes in insulin secretion or insulin sensitivity (). In the same way, acute ICV injections of FGF reduce plasma glucose, corticosterone, and ACTH, independently of any change in plasma insulin and glucagon, in an insulinopenic rat model of TD (). In this study, FGF suppresses hepatic glucose production by reducing hepatic acetyl CoA levels (). Indeed, the glucoselowering action of FGF is due to the suppression of the hypothalamic-pituitary-adrenal axis (). In line with the insulin-independent glucose lowering effect of FGF/ signaling, FGF KO mice show impaired glucose uptake from the circulation () and more elevated postprandial glycemia compared with wild-type mice, without any change in insulin sensitivity or glucagon concentrations ().
Pleiotropic functions of FGF/ in animals and humans are illustrated in Fig. . 
FGF19 in Human Diseases
Obesity and diabetes
Obesity Several studies have reported that basal circulating FGF levels are significantly lower in obese patients relative to nonobese controls, without any strong relationship to glucose metabolism or insulin sensitivity (, -). This suggests that excessive weight in itself drives the decrease in FGF levels. In this way, FGF levels are mainly correlated to visceral adiposity (, ). Moreover, expression of KLB is significantly decreased in the visceral adipose tissue of obese patients, whereas it is increased in their liver (). Nevertheless,  weeks to  months of lifestyleinduced weight loss does not consistently restore basal and postprandial circulating levels of FGF (, , ).
Type 2 Diabetes
Other studies report that basal circulating FGF levels are inversely correlated to glucose metabolism or insulin sensitivity. Notably, patients with metabolic syndrome or TD have lower circulating FGF levels than do healthy controls (, , ). Moreover, basal FGF levels are negatively associated with fasting glycemia and independently associated with the deterioration of glucometabolic status (). Patients with TD have lower circulating FGF levels than do nondiabetic patients, irrespective of body weight (). Circulating levels of FGF are also significantly reduced in women with gestational diabetes mellitus relative to healthy pregnant women ().
Liver and biliary diseases NAFLD Some studies report that patients with NAFLD present similar basal FGF levels to healthy subjects (, ). Nevertheless, their hepatic response to FGF is impaired when they present insulin resistance (). Other studies show that FGF levels are significantly lower in patients with NAFLD than in controls (, ). This decrease could be related to reduced FGF production caused by a disproportionate increase in the amount of DCA at the expense of CDCA (a most potent FXR agonist) (). In obese adolescents with NAFLD, FGF levels are dampened compared with controls, with an inverse correlation between FGF, alanine aminotransferase, and triglyceride levels (). In children with NAFLD, serum FGF is inversely associated with hepatic damage (, ). KLB expression decreases in children livers with increasing severity of NAFLD ().
In a recent phase  clinical study, the reengineered FGF analog NGM (also known as M in preclinical studies) produced a rapid and significant reduction in liver fat content in patients with NASH (). In fact, after  weeks of treatment ( or  mg SC) % of patients achieved a reduction of .% in fat content, associated with significant reductions in both alanine aminotransferase and aspartate aminotransferase (). Liver fat content is completely normalized in % to % of patients ().
Cirrhosis FGF expression is increased in cholestatic noncirrhotic and cirrhotic livers compared with control livers (, ). Both circulating and hepatic levels of FGF correlate with the severity of hepatic disease (). Circulating FGF levels are higher in cirrhotic patients with primary biliary cirrhosis compared with noncirrhotic patients with primary biliary cirrhosis or healthy individuals (). FGF levels are strongly correlated with BA synthesis and the severity of cholestasis (). Administration of the FXR agonist obeticholic acid increases FGF levels in patients with primary biliary cirrhosis and improves markers of the disease, such as the alkaline phosphatase and total bilirubin levels (). In patients with alcoholic hepatitis, circulating FGF levels are strongly increased and gene expression of FGF is induced in biliary epithelial cells and ductular cells (). FGF levels correlate positively with total and conjugated BAs (in particular with conjugated CA), as well as with disease severity ().
Cholelithiasis/primary sclerosing cholangitis
The expression of FGF is reduced in ileal biopsies of gallstone carriers with normal weight (), but circulating FGF levels are not related to the history of cholecystectomy (). A marked elevation of circulating FGF levels is observed in patients with extrahepatic cholestasis caused by a pancreatic tumor (). In patients with sclerosing cholangitis, basal FGF levels are unchanged (). However, these patients exhibit a prolonged FGF peak in the circulation following a CDCA oral challenge () as well as increased FGF protein content in the ascending colon (). UDCA withdrawal does not change circulating FGF levels in patients with primary sclerosing cholangitis ().
Intestinal diseases
Patients with BA malabsorption BA malabsorption leads to excessive fecal BA excretion and diarrhea. It is also associated with lack of feedback regulation, resulting in additional BA production, saturating ileal transport. Circulating FGF levels are significantly lower in patients with BA malabsorption compared with controls (, , ), whereas a subgroup of hypertriglyceridemic patients presented higher values (). Impairment in ileal FGF expression and responsiveness contributes to the multifactorial etiology of primary BA diarrhea (-). FGF represents both an opportunity for diagnosis and treatment of the pathophysiological defect. From a genetic point of view, a DIET coding variant, which increases the amount of FGF secreted, has a skewed prevalence between patients with BA diarrhea and controls (), suggesting that genetic variation impacting FGF secretion also affects BA metabolism in pathological conditions ().
Inflammatory bowel syndrome
Patients with inflammatory bowel syndrome (IBS) have similar FGF levels to controls (, ), but a subset of IBS patients with low BA turnover rate presents lower FGF levels (). Variants in KLB and FGFR may identify subgroups of patients with IBS showing () elevated serum a-hydroxy--cholesten--one (), () changes in BA/colonic transit (, ), or () a positive response to treatment with BA sequestrants (). In pediatric onset of intestinal failure, total or partial loss of the ileum decreases circulating FGF levels (, ). In these patients, FGF levels negatively correlate with the extent of portal inflammation, serum TNF-a, and hepatic fibrosis stage (). Low FGF levels are also associated with liver injury featured by liver bile duct proliferation, inflammatory infiltration, predominance of primary BA, hepatocyte apoptosis, and fibrosis (). Reduced FGF levels are associated with ileal resection, diarrhea, and Crohn's disease activity, suggesting a role of FGF as a biomarker for diseases affecting the ileum (). FGF levels are decreased in patients with Crohn's disease when compared with healthy controls, or even when compared with patients with ulcerative colitis ().
Renal diseases
Circulating FGF levels are increased during endstage renal disease in patients undergoing chronic hemodialysis compared with normal subjects (). The postprandial FGF response is also blunted in patients with chronic kidney disease compared with control subjects, in association with impaired insulin and C-peptide signaling ().
Cancer
HCC
The action of FGF on hepatocyte proliferation observed in mice and cell culture suggests a role in the occurrence or progression of HCC in humans. FGF and FGFR are coexpressed in primary human liver tumors (). FGFR expression is elevated in liver tumors relative to normal tissues (). FGF is equally significantly overexpressed in HCC compared with corresponding noncancerous liver tissue and is an independent negative prognostic factor for survival (, , , ). Expression of FGF is associated significantly with larger tumor size () and correlates with sensitivity of cells to FGFR inhibitors (). Hepatic tissue protein content of FGF and FGFR significantly correlates with histopathologic changes from fatty liver to HCC (). FGF levels are also significantly increased in the circulation of patients with HCC compared with controls () and are lowered after surgical tumor resection (). A positive correlation is observed between the expression of FGF and the epidermal growth factor receptor ligand amphiregulin (), whereas FGF expression is negatively associated with the expression of E-cadherin in HCC tissues (), thus highlighting a role in epithelial-mesenchymal transition. FGF expression is also correlated with the expression levels of STAT target genes in HCC tumors (). High expression of FGF signaling actors and low expression of FGF signaling repressors correlate with the aggressiveness of hepatoblastoma tumors in children ().
In addition to the overexpression of FGF in hepatic tumors, amplification of the FGF gene region is also observed in HCC, corroborating a role as a tumor-promoting gene (). Genomic profiling of HCC at early stages reveals high copy number amplifications of the gene region, including the FGF gene in % of cases, in association with liver cirrhosis, especially in patients infected with hepatitis B (). FGF amplification is also observed at advanced stages in aggressive HCC tumors (). A gain in FGF copy number is detected more frequently among patients with a complete response to the multikinase inhibitor sorafenib compared with patients with incomplete response (). Genetic alterations in FGFR, including frequent polymorphisms, are also observed in HCC tissues compared with control tissue pairs (). In vitro FGF stimulation confirmed a mechanistic link between FGFR activities and tumor aggressiveness in HCC cell lines (). The inhibition of FGF/FGFR signaling overcomes sorafenib resistance (, ). In a genome-wide mapping of DNA methylation, the FGF gene appears significantly hypermethylated in the tumor tissues compared with paired adjacent peritumoral tissues (). Therapeutic approaches targeting FGFR in HCC, including ongoing clinical trials, have been previously reviewed ().
Digestive tract cancers FGF is overexpressed in gastric cancer and is associated with depth of invasion and lymph node metastasis (). In vitro, FGF enhances migration and the invasion abilities of gastric cancer cells ().
FGF and FGFR are coexpressed in primary human colon tumors and in a subset of human colon cancer cell lines (). In these cells, FGF increases tyrosine phosphorylation of b-catenin and inhibits b-catenin/E-cadherin binding (), suggesting that inactivation of FGF/FGFR signaling could be a therapeutic target. FGF is required for PXR-induced cell growth, invasion, and metastasis in both human colonic tumor cell lines and mice xenografted with tumor cells (). PXR binds to the FGF promoter in human colon tumor cells as well as in normal intestinal crypt cells, but promoter activation occurs only in cancer cells ().
The implication of FGF in pancreatic tumors and cholangiocarcinoma remains more elusive. FGFR expression is markedly increased in high-grade pancreatic ductal adenocarcinoma and pancreatic intraepithelial neoplasia compared with the normal pancreas (). FGF seems to contribute to tumor suppression by increasing cellular adhesion to the extracellular matrix in pancreatic ductal adenocarcinoma cells (). FGF expression is reduced in cholangiocarcinoma tumors compared with normal bile duct tissue (). In intrahepatic cholangiocarcinoma, high expression of FGF is significantly associated with better survival ().
Reproductive tissues cancers
In addition to hepatic and gastrointestinal cancers, several studies have implicated FGF in cancers of reproductive tissues, including the prostate, ovary, and breast.
FGF is expressed in primary and metastatic prostate cancer tissues, where it functions as an autocrine growth factor (). Exogenous FGF promotes growth, invasion, adhesion, and colony formation of prostate cancer cells (). In contrast, FGF silencing in prostate cancer cells expressing autocrine FGF decreases invasion and proliferation in vitro and tumor growth in vivo (). Moreover, higher levels of prostate-specific antigen are observed in patients with prostate tumors positive for FGF staining, and survival is higher in patients with FGF-negative tumors (). FGF enhances the viability and the expression of N-cadherin in human prostate adenocarcinoma cells while suppressing the expression of E-cadherin and caspase  ().
High expression of FGF predicts unfavorable prognosis of advanced-stage serous ovarian cancer (). In vitro, FGF promotes ovarian cancer cell proliferation and invasion by activating the FGFR-Akt-MAPK signaling pathway ().
FGF is also involved in breast cancer (). FGFR/FGF coexpression is observed in almost one third of primary breast tumors (). A subset of basallike breast cancer cells secretes FGF, and FGFR is a mediator of cell survival via activation of phosphatidylinositol -kinase/Akt signaling (). The YC missense mutation in FGFR in a human breast cancer cell line confers insensitivity to FGFR ligand stimulation, but it elicits a constitutive phosphorylation leading to activation of the MAPK cascade-driven tumor growth ().
Other cancers FGF expression is observed in most malignant cells of patients with thyroid cancer (). The amount of FGF protein in thyroid cancer tissues is significantly higher than in normal tissues (). FGF overexpression is also significantly associated with advanced stages of the disease, including tumor node metastasis, extrathyroidal invasion, and distant metastasis (). Amplification of the FGF genic region is observed in a subset of patients with advanced medullary thyroid carcinoma (). Higher circulating levels of FGF are found in patients with papillary thyroid cancer, follicular thyroid cancer, and anaplastic thyroid cancer when compared with patients with multinodular nontoxic goiter and with healthy controls (). FGF is equally highly expressed in mesenchymal stem cells/exosomes, which accelerates nasopharyngeal carcinoma progression (). FGF and FGFR are also coexpressed in primary human lung tumors (). In patients with lung squamous cell carcinoma, amplification of the FGF genic region, as well as gene overexpression in the tumor compared with adjacent nontumoral tissues, is found more frequently with smoking (, ).
Conclusions and Perspectives
Human FGF and its murine FGF homolog are fascinating hormones harboring a wide diversity of actions, from fetal morphogenesis to stimulation of adult tissue growth (liver, muscle), through control of BA synthesis and insulin-like postprandial activity. Moreover, administration of supraphysiological doses of FGF strikingly mimics the effects of FGF, increasing energy expenditure and glucose utilization. These biological properties explain the strong scientific enthusiasm for these molecules and the optimism concerning their use as metabolic drugs.
Based on the evolutionary conservation of their surrounding genetic loci, FGF and FGF genes are considered as orthologs (). However, their homology is weaker than all other human/mouse FGF family members (), suggesting some divergence in terms of production and biological actions. FGF and FGF are both highly expressed in the ileum. In the liver, FGF is absent in mice (, ) but FGF is induced in humans under cholestatic conditions (-, , ), raising questions about this tissular contribution. Additionally, high levels of FGF are observed in human bile (, ) due to high production levels in gallbladder cholangiocytes and extrahepatic bile duct (, ). This suggests either an exocrine or a paracrine function (anti-inflammatory, secretagogue?), which remains to be elucidated. Molecular regulation of FGF and FGF also reveal some differences, in particular concerning the nuclear receptors involved. Furthermore, the role of gut microbiota in the regulation of FGF/ is not fully elucidated in mice and is presently unknown in humans.
Beyond their regulation, FGF and FGF also present structural divergences. Of note, FGF contains a specific unpaired cysteine residue, which allows dimerization of FGF monomers (). Thus, conformational divergence between FGF and FGF could induce differences in ligand-receptor affinity and explain functional disparities. The systemic effect of FGF has long been underinvestigated due to the instability of the molecule (, , ). In contrast, human FGF has been intensively studied in mice, albeit with concerns about technical bias and limitations associated with the use of human FGF in murine models (expressing mouse FGFRs). Moreover, clinical studies, as well as human primary cultures, reveal some differences from what is observed in mice, complicating the translation of mouse-derived knowledge to the human situation. The understanding of the role of FGF/ in metabolism is further complicated by the fact that beyond metabolic consequences directly resulting from FGFR signaling, FGF/ also modulates levels and composition of BAs, master regulators of energy expenditure, as well as lipid and glucose metabolism. In fact, both FGF and FGF repress hepatic BA production and shift "Several studies have implicated FGF19 in cancers of reproductive tissues."
BA synthesis from the neutral to the alternative BA synthesis pathway. However, owing to differences in BA metabolism among species, FGF action increases hydrophilicity of the BA pool in rodents, whereas FGF increases hydrophobicity of the BA pool in humans. This effect on BA composition also impacts differently FXR and TGR signaling in mice and humans and deserves further metabolic investigation. New animal models more closely mimicking human physiology in terms of BA biology could provide functional and mechanistic insights that better delineate particular clinical situations. FGF appears more potent than FGF for correcting murine obesity (). However, unlike FGF, FGF induces hepatocyte proliferation and ultimately HCC in mice (). This side effect has dampened the interest of several pharmaceutical companies for FGF, leading them to focus on nonmitogenic FGF as a metabolic drug candidate. The action of FGF on hepatocyte proliferation is directly dependent on STAT activation and downstream target genes (, , ). Reengineering of FGF allows suppression of its ability to induce STAT phosphorylation and thus its oncogenicity (). Thus, genetically modified FGF (M) retains biological properties and protects mice from cholestatic liver injury (, , ). From a translational point of view, this compound also reduces BA synthesis in humans () and is currently being tested in patients suffering from primary biliary cirrhosis and TD () . More recent studies demonstrate that M reduces hepatic fat content in patients with NASH in a phase  clinical trial (), currently representing the most significant advance in the use of FGF as a drug.
FGF has grown in interest for treating obesity and TD (). Nevertheless, it is already upregulated during metabolic diseases, reflecting either a compensatory mechanism to limit metabolic insults or a state of FGF resistance. In contrast, FGF levels are decreased in human metabolic diseases, including obesity (, -), TD (, , , , ), or NAFLD (, ). Even if these clinical studies are correlative in nature and do not provide mechanistic explanations, they support supplemental approaches to treat metabolic and hepatic diseases. Moreover, in addition to its FGF-like glucose lowering activity, FGF could also be beneficial in diseases involving BA excess or gut-related FGF deficiency. Alternatively, FGF is overexpressed in HCC tumors compared with corresponding control hepatic tissue (, , , ). This suggests that inhibition/blockade of FGF signaling can also be beneficial in this pathological context in which novel therapeutic approaches are also urgently needed.
